M
Miyako Satouchi
Researcher at Kobe University
Publications - 177
Citations - 14321
Miyako Satouchi is an academic researcher from Kobe University. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 38, co-authored 164 publications receiving 12197 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
Journal Article
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
Hirokazu Watanabe,Morihito Okada,Yasushi Kaji,Miyako Satouchi,Yozo Sato,Yuichiro Yamabe,Hiroaki Onaya,Masahiro Endo,Miyuki Sone,Yasuaki Arai +9 more
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal ArticleDOI
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida,Hiroshi Nokihara,Masashi Kondo,Young Hak Kim,Koichi Azuma,Takashi Seto,Yuichi Takiguchi,Makoto Nishio,Hiroshige Yoshioka,Fumio Imamura,Katsuyuki Hotta,Satoshi Watanabe,Koichi Goto,Miyako Satouchi,Toshiyuki Kozuki,Takehito Shukuya,Kazuhiko Nakagawa,Tetsuya Mitsudomi,Nobuyuki Yamamoto,Takashi Asakawa,Ryoichi Asabe,Tomohiro Tanaka,Tomohide Tamura +22 more
TL;DR: These results provide the first head-to-head comparison of alectinib and crizotinib and have the potential to change the standard of care for the first-line treatment of ALK-positive non-small-cell lung cancer.
Journal ArticleDOI
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood D. Goss,Chun-Ming Tsai,Frances A. Shepherd,Lyudmila Bazhenova,Jong Seok Lee,Gee-Chen Chang,Lucio Crinò,Miyako Satouchi,Quincy Chu,Toyoaki Hida,Ji-Youn Han,Oscar Juan,Frank Dunphy,Makoto Nishio,Jin-Hyoung Kang,Margarita Majem,Helen Mann,Mireille Cantarini,Serban Ghiorghiu,Tetsuya Mitsudomi +19 more
TL;DR: Osimertinib showed clinical activity with manageable side-effects in patients with EGFR Thr790Met-positive non-small-cell lung cancer and could be a suitable treatment for patients who have progressed on an EGFR tyrosine-kinase inhibitor.
Journal ArticleDOI
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon,Geoffrey R. Oxnard,Daniel Shao-Weng Tan,Herbert H. Loong,Melissa Lynne Johnson,Justin F. Gainor,Caroline E. McCoach,Oliver Gautschi,Benjamin Besse,Byoung Chul Cho,Nir Peled,Jared Weiss,Yu-Jung Kim,Yuichiro Ohe,Makoto Nishio,Keunchil Park,Jyoti D. Patel,Takashi Seto,Tomohiro Sakamoto,Ezra Rosen,Manisha H. Shah,Fabrice Barlesi,Philippe A. Cassier,Lyudmila Bazhenova,Filippo de Braud,Elena Garralda,Vamsidhar Velcheti,Miyako Satouchi,Kadoaki Ohashi,Nathan A. Pennell,Karen L. Reckamp,Grace K. Dy,Jürgen Wolf,Benjamin Solomon,Gerald Steven Falchook,Kevin Ebata,Michele Nguyen,Binoj Nair,Edward Y. Zhu,L. Yang,Xin Huang,Elizabeth Olek,S. Michael Rothenberg,Koichi Goto,Vivek Subbiah +44 more
TL;DR: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated.